Fred Hutchinson bone marrow transplant program receives national recognition
The Center for International Blood and Marrow Transplant Research’s annual report recognized the Fred Hutchinson Cancer Center bone marrow transplant program at Seattle Cancer Care Alliance for better-than-expected 1-year survival rates.
This is the sixth year the Fred Hutch program — which began more than 40 years ago and has performed more than 16,000 transplants — has earned this recognition, an accomplishment that only four other transplant centers have achieved.
“Patients want to be assured that they’re receiving the best care to support survival, outstanding treatment outcomes and continuous quality of life, and we’re proud of our record of 6 continuous years surpassing the expected survival rates for our allogeneic bone marrow transplant program,” Nancy E. Davidson, MD, president and executive director of Seattle Cancer Care Alliance and senior vice president of the clinical research division at Fred Hutch, said in a press release. “Continued recognition by notable organizations like Center for International Blood and Marrow Transplant Research, the National Cancer Institute and others provides credibility to support and reassure patients and referring physicians that the partners in our alliance make a marked difference in providing high-quality, validated options for cancer care.”
For the annual report, researchers of Center for International Blood and Marrow Transplant Research assessed survival rates of 24,141 allogenic transplants performed at 177 transplant centers between 2014 and 2016. In total, 788 of these transplants were conducted at Fred Hutch.
“We are extremely proud that patients receiving allogeneic bone marrow transplants at Seattle Cancer Care Alliance can expect survival rates that are consistently better than the expected 1-year survival rates,” Marco Mielcarek, MD, medical director for the adult bone marrow transplant program at Seattle Cancer Care Alliance and member of the clinical research division at Fred Hutch, said in the release. “Outcomes are attributable to many factors, but our dedicated team and their decades of transplant experience and groundbreaking research are important contributors to sustaining exceptional outcomes. Our research has yielded consistent improvements in efficacy and safety of stem cell transplantation. Our team is committed to continued improvements in outcomes for all our patients.”